J Reynes

Summary

Country: France

Publications

  1. ncbi Suppression of HIV-1 replication by microRNA effectors
    Christine Chable-Bessia
    Institut de Génétique Humaine CNRS UPR1142, Laboratoire de Virologie Moleculaire, Montpellier, France
    Retrovirology 6:26. 2009
  2. ncbi Unintegrated HIV-1 provides an inducible and functional reservoir in untreated and highly active antiretroviral therapy-treated patients
    Gael Petitjean
    Laboratoire de Virologie, Hopital Lapeyronie, avenue du Doyen Gaston Giraud, 34295 Montpellier, France
    Retrovirology 4:60. 2007
  3. ncbi [Antiretroviral therapies: strategic perspectives for the future]
    J Reynes
    Service des Maladies Infectieuses et Tropicales, , CHU de Montpellier, France
    Med Trop (Mars) 67:367. 2007
  4. ncbi TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals
    Jacques Reynes
    Hopital Gui de Chauliac, CHU Montpellier, France
    AIDS Patient Care STDS 21:533-43. 2007
  5. ncbi Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study
    Roland Landman
    Service des Maladies Infectieuses et Tropicales, AP HP, Groupe Hospitalier Bichat Claude Bernard, Paris, France
    J Antimicrob Chemother 64:118-25. 2009
  6. ncbi Perforin expression in T cells and virological response to PEG-interferon alpha2b in HIV-1 infection
    Pierre Portales
    Laboratoire d'Immunologie, , Service des Maladies Infectieuses et Tropicales, , Montpellier, France
    AIDS 17:505-11. 2003
  7. ncbi Diagnostic approaches to imported schistosomal myeloradiculopathy in travelers
    A Makinson
    Department of Infectious Diseases, University Hospital, Montpellier, F-34295 Montpellier, France
    Neurology 71:66-7. 2008
  8. ncbi Pregnancy may be followed by an inflexion of the immune reconstitution in HIV-infected women who receive antiretroviral drugs before conception
    V Le Moing
    Centre Hospitalier Universitaire, Montpellier, France
    HIV Med 9:897-900. 2008
  9. ncbi Necrotizing cutaneous lesions complicating treatment with pegylated-interferon alfa in an HIV-infected patient
    Didier Bessis
    Service de Dermatologie Phlébologie, CHU Montpellier, Hopital Saint Eloi, 80, avenue Augustin Fliche, 34295 Montpellier Cedex 5, France
    Eur J Dermatol 12:99-102. 2002
  10. ncbi Molecular diagnosis of culture-negative cerebral nocardiosis due to Nocardia abscessus
    Helene Marchandin
    Laboratoire de Bacteriologie, Hopital Arnaud de Villeneuve, 34295 Montpellier Cedex 5, France
    Diagn Microbiol Infect Dis 55:237-40. 2006

Detail Information

Publications63

  1. ncbi Suppression of HIV-1 replication by microRNA effectors
    Christine Chable-Bessia
    Institut de Génétique Humaine CNRS UPR1142, Laboratoire de Virologie Moleculaire, Montpellier, France
    Retrovirology 6:26. 2009
    ..Interestingly, knockdown of RCK/p54 or DGCR8 resulted in virus reactivation in PBMCs isolated from HIV infected patients treated with suppressive HAART...
  2. ncbi Unintegrated HIV-1 provides an inducible and functional reservoir in untreated and highly active antiretroviral therapy-treated patients
    Gael Petitjean
    Laboratoire de Virologie, Hopital Lapeyronie, avenue du Doyen Gaston Giraud, 34295 Montpellier, France
    Retrovirology 4:60. 2007
    ..The presence of HIV-1 preintegration reservoir was assessed in an in vitro experimental model of latent HIV-1 infection, and in patients treated or not with highly active antiretroviral therapy (HAART)...
  3. ncbi [Antiretroviral therapies: strategic perspectives for the future]
    J Reynes
    Service des Maladies Infectieuses et Tropicales, , CHU de Montpellier, France
    Med Trop (Mars) 67:367. 2007
  4. ncbi TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals
    Jacques Reynes
    Hopital Gui de Chauliac, CHU Montpellier, France
    AIDS Patient Care STDS 21:533-43. 2007
    ..In conclusion, these data demonstrate durable efficacy and safety of ENF over 96 weeks and that early use of ENF in combination with other agents for the treatment of antiretroviral-experienced HIV-infected subjects is beneficial...
  5. ncbi Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study
    Roland Landman
    Service des Maladies Infectieuses et Tropicales, AP HP, Groupe Hospitalier Bichat Claude Bernard, Paris, France
    J Antimicrob Chemother 64:118-25. 2009
    ..We evaluate the efficacy and tolerability of ritonavir-boosted dual protease inhibitor as a nucleoside reverse transcriptase inhibitor-sparing regimen in a prospective open-label randomized pilot trial in antiretroviral-naive patients...
  6. ncbi Perforin expression in T cells and virological response to PEG-interferon alpha2b in HIV-1 infection
    Pierre Portales
    Laboratoire d'Immunologie, , Service des Maladies Infectieuses et Tropicales, , Montpellier, France
    AIDS 17:505-11. 2003
    ..647; P= 0.017). CONCLUSION: The pre-therapeutic percentage of perforin-positive T cells might be a predictive marker of the virological response to IFNalpha in HIV-1-infected patients...
  7. ncbi Diagnostic approaches to imported schistosomal myeloradiculopathy in travelers
    A Makinson
    Department of Infectious Diseases, University Hospital, Montpellier, F-34295 Montpellier, France
    Neurology 71:66-7. 2008
  8. ncbi Pregnancy may be followed by an inflexion of the immune reconstitution in HIV-infected women who receive antiretroviral drugs before conception
    V Le Moing
    Centre Hospitalier Universitaire, Montpellier, France
    HIV Med 9:897-900. 2008
    ..Whether pregnancy has an impact on the evolution of CD4 cell counts in women treated with highly potent antiretrovirals before conception remains largely unknown...
  9. ncbi Necrotizing cutaneous lesions complicating treatment with pegylated-interferon alfa in an HIV-infected patient
    Didier Bessis
    Service de Dermatologie Phlébologie, CHU Montpellier, Hopital Saint Eloi, 80, avenue Augustin Fliche, 34295 Montpellier Cedex 5, France
    Eur J Dermatol 12:99-102. 2002
    ..We review the literature on previously reported cases of cutaneous necrosis following standard or pegylated IFN-alpha injection and discuss the different pathophysiological mechanisms that might be involved...
  10. ncbi Molecular diagnosis of culture-negative cerebral nocardiosis due to Nocardia abscessus
    Helene Marchandin
    Laboratoire de Bacteriologie, Hopital Arnaud de Villeneuve, 34295 Montpellier Cedex 5, France
    Diagn Microbiol Infect Dis 55:237-40. 2006
    ..The patient is alive and well on imipenem and doxycycline therapy, 14 months after onset...
  11. ncbi Reasons for early abacavir discontinuation in HIV-infected patients
    Helene Peyriere
    Pharmacovigilance Center, Lapeyronie Hospital, Montpellier, France
    Ann Pharmacother 37:1392-7. 2003
    ..To determine incidence of and reasons for discontinuation of abacavir within the first 6 months of therapy...
  12. ncbi Efficacy of ceftriaxone and doxycycline in the treatment of early syphilis
    K C Psomas
    Departement des Maladies Infectieuses et Tropicales, Hopital Gui de Chauliac, Montpellier Cedex, France
    Med Mal Infect 42:15-9. 2012
    ..An increase of syphilis cases has been recorded in the past few decades, especially among HIV-infected patients. These patients often present with concomitant primary and secondary lesions or extensive presentations of syphilis...
  13. ncbi CD4 T cell surface CCR5 density as a host factor in HIV-1 disease progression
    J Reynes
    Service des Maladies Infectieuses et Tropicales, , Montpellier, France
    AIDS 15:1627-34. 2001
    ..Consequently, CCR5 density quantitation could be a new valuable prognostic tool in HIV-1 infection. Moreover, these data emphasize the therapeutic potential of treatments that reduce functional CCR5 density...
  14. ncbi The fusion inhibitor enfuvirtide in recent antiretroviral strategies
    Alain Makinson
    Infectious Diseases Department, Montpellier University Hospital, CHU Montpellier, France
    Curr Opin HIV AIDS 4:150-8. 2009
    ..The purpose of this review is to discuss recent pharmacological, virological, and clinical data that concern enfuvirtide usage in different antiretroviral combinations...
  15. ncbi Interferon-alpha restores HIV-induced alteration of natural killer cell perforin expression in vivo
    Pierre Portales
    Laboratoire d'Immunologie, , the Service des Maladies Infectieuses et Tropicales, , Montpellier, France
    AIDS 17:495-504. 2003
    ....
  16. ncbi [Ocular bartonellosis in an HIV-HVC coinfected patient]
    C Merle De Boever
    Service Maladies Infectieuses et Tropicales, CHU de Montpellier, 80 avenue Augustin Flèche, Montpellier, France
    Med Mal Infect 38:504-6. 2008
    ..Nuclear magnetic resonance revealed a retrobulbar neuritis. Confirmation was given by blood tests positive for B. henselae and the exclusion of other causes of neuroretinitis with biological data. Doxycycline cured the disease rapidly...
  17. ncbi Profound neutropenia resulting from interaction between antiretroviral therapy and vinblastine in a patient with HIV-associated Hodgkin's disease
    Alain Makinson
    Infectious Diseases Department, Gui de Chauliac Hospital, CHU Montpellier, France
    Eur J Haematol 78:358-60. 2007
    ..This unrecorded strategy is discussed...
  18. ncbi Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases
    Helene Peyriere
    Department of Medical Pharmacology, Lapeyronie Hospital, CHU Montpellier, France
    J Acquir Immune Defic Syndr 35:269-73. 2004
    ..In patients with low weight or mild preexisting renal impairment, regular monitoring of tubulopathy markers could lead to early detection of this dysfunction...
  19. ncbi [Assessment of renal abnormalities in 107 HIV patients treated with tenofovir]
    Pierre Lochet
    Service des Maladies Infectieuses et Tropicales, , CHU Montpellier, Montpellier, France
    Therapie 60:175-81. 2005
    ..6; p = 0.03). Frequency of abnormal proteinuria was 22%. CONCLUSION: Creatinine clearance, phosphataemia, proteinuria and glycosuria should be closely monitored in patients receiving tenofovir therapy...
  20. ncbi Characterization of genotypic determinants in HR-1 and HR-2 gp41 domains in individuals with persistent HIV viraemia under T-20
    Anne Genevieve Marcelin
    Pitie Salpetriere Hospital, Paris, France
    AIDS 18:1340-2. 2004
    ..Our results suggest that only HR-1 sequencing is necessary to characterize resistance to T-20, and that HR-2 domain sequencing is probably not required...
  21. ncbi Concomitant use of an active boosted protease inhibitor with enfuvirtide in treatment-experienced, HIV-infected individuals: recent data and consensus recommendations
    Mike Youle
    Royal Free Hospital Centre for HIV Medicine, Royal Free Hospital, London, UK
    HIV Clin Trials 7:86-96. 2006
    ..g., ENF) for triple-class-experienced patients...
  22. ncbi Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks
    Benoit Trottier
    Clinique Médicale l Actuel, Montreal, Quebec, Canada
    J Acquir Immune Defic Syndr 40:413-21. 2005
    ..The T-20 Versus Optimized Background Regimen Only (TORO) studies assessed the safety and efficacy of enfuvirtide in treatment-experienced HIV-1-infected patients...
  23. ncbi The immunological response to highly active antiretroviral therapy is linked to CD4+ T-cell surface CCR5 density
    Thierry Vincent
    J Acquir Immune Defic Syndr 43:377-8. 2006
  24. ncbi Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults
    Dirk Schurmann
    Charite Universitatsmedizin, Berlin, Germany
    AIDS 21:1293-9. 2007
    ..To determine antiviral activity, pharmacokinetic properties, and safety of vicriviroc, an orally available CCR5 antagonist, as monotherapy in HIV-infected patients...
  25. ncbi Dynamics of spontaneous HIV-1 specific and non-specific B-cell responses in patients receiving antiretroviral therapy
    Anne-Marie Fournier
    , , 34295 Montpellier Cedex 5, France
    AIDS 16:1755-60. 2002
    ..These results pointed out that HIV-1 specific antibody secretion persisted in 11 out of 17 SR patients, suggesting persistent immune system activation by residual HIV-1 antigens...
  26. ncbi Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia
    Adriano Lazzarin
    Istituto di Ricovero e Cura a Carattere Scientifico, San Raffaele Vita Salute University, Milan, Italy
    N Engl J Med 348:2186-95. 2003
    ....
  27. ncbi Long-term persistence of memory B cells specific for hepatitis B surface antigen in HIV-1-infected patients
    Edouard Tuaillon
    Laboratoire de Virologie, Hopital Lapeyronie, Montpellier, France
    AIDS 21:2343-5. 2007
    ..A lower number of HBs-SC was found in HBsAg-vaccinated patients compared with vaccinated controls...
  28. ncbi Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro
    Isabelle Malet
    Laboratoire de Virologie, Hopital Pitie Salpetriere, Assistance Publique Hopitaux de Paris, EA 2387, Universite Pierre et Marie Curie Paris 6, Paris, France
    Antimicrob Agents Chemother 52:1351-8. 2008
    ..These mutations led to strong impairment of enzymes in vitro in the absence of raltegravir: strand transfer activity was affected, and in some cases 3' processing was also impaired...
  29. ncbi Cell surface CCR5 density determines the postentry efficiency of R5 HIV-1 infection
    Yea-Lih Lin
    , Centre National de la Recherche Scientifique, , , France
    Proc Natl Acad Sci U S A 99:15590-5. 2002
    ..These data explain why CCR5 density influences HIV-1 disease progression and underline the therapeutic interest of lowering CCR5 expression...
  30. ncbi [New antiretroviral treatment modalities]
    Jacques Reynes
    Service des Maladies Infectieuses et Tropicales, UMR 145 VIH et Maladies Associées Hôpital Gui de Chauliac, 34295 Montpellier
    Presse Med 34:1S23-30. 2005
    ..For non-responders, thorough virological-pharmacological assessment is necessary, together with access to new molecules and new drug classes...
  31. ncbi Maraviroc for previously treated patients with R5 HIV-1 infection
    Roy M Gulick
    Weill Cornell Medical College, New York, NY 10065, USA
    N Engl J Med 359:1429-41. 2008
    ..CC chemokine receptor 5 antagonists are a new class of antiretroviral agents...
  32. ncbi Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection
    Gerd Fatkenheuer
    Universitätsklinik Köln, Cologne, Germany
    N Engl J Med 359:1442-55. 2008
    ....
  33. ncbi Pharmacokinetics of plasma enfuvirtide after subcutaneous administration to patients with human immunodeficiency virus: Inverse Gaussian density absorption and 2-compartment disposition
    Xiaoping Zhang
    Department of Clinical Pharmacology, Hoffmann La Roche Inc, Nutley, NJ 07110, USA
    Clin Pharmacol Ther 72:10-9. 2002
    ....
  34. ncbi Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials
    Mark Nelson
    Chelsea and Westminster Hospital, London, United Kingdom
    J Acquir Immune Defic Syndr 40:404-12. 2005
    ....
  35. ncbi Low CD4+ T-cell surface CCR5 density as a cause of resistance to in vivo HIV-1 infection
    Jacques Reynes
    J Acquir Immune Defic Syndr 34:114-6. 2003
  36. ncbi The efficiency of R5 HIV-1 infection is determined by CD4 T-cell surface CCR5 density through G alpha i-protein signalling
    Yea-Lih Lin
    , CNRS UPR1142, Montpellier, France
    AIDS 20:1369-77. 2006
    ..This observation sheds new light on the physiopathology of HIV infection, and opens new therapeutic opportunities targeting G alpha i signalling...
  37. ncbi Benefit of treatment interruption in HIV-infected patients with multiple therapeutic failures: a randomized controlled trial (ANRS 097)
    Christine Katlama
    Département des Maladies Infectieuses et Tropicales INSERM E 0214, Hopital Pitie Salpetriere, 47 83 boulevard de l Hopital, 75651 Paris Cedex 13, France
    AIDS 18:217-26. 2004
    ..Both highly potent antiretroviral drug rescue therapy and treatment interruption have been suggested to be effective in patients with multiple treatment failure...
  38. ncbi Human immunodeficiency virus type 1 (HIV-1) antigen secretion by latently infected resting CD4+ T lymphocytes from HIV-1-infected individuals
    Jean-Michel Fondere
    Laboratoire de Virologie, , avenue du Doyen Gaston Giraud, 34295 Montpellier, France
    J Virol 78:10536-42. 2004
    ..The ELISPOT approach to targeting the HIV-1-Ag-SCs could be a useful method for identifying latently HIV-1-infected CD4(+) T cells carrying replication-competent HIV-1 in patients responding to HAART...
  39. ncbi Vitamin E supplementation increases the expression of the CCR5 coreceptor in HIV-1 infected subjects
    Pierre Portales
    Clin Nutr 23:1244-5. 2004
  40. ncbi Comparison of drug resistance mutations and their interpretation in patients infected with non-B HIV-1 variants and matched patients infected with HIV-1 subtype B
    Brigitte Montes
    Department of Virology, University Hospital of Montpellier, Montpellier, France
    J Acquir Immune Defic Syndr 35:329-36. 2004
    ..CONCLUSION: Our results suggest that the genetic diversity of HIV-1 does not play a major role in the development of resistance to antiretroviral drugs...
  41. ncbi Relationship between CCR5 density and viral load after discontinuation of antiretroviral therapy
    Jacques Reynes
    JAMA 291:46. 2004
  42. ncbi T-Cell surface CCR5 density is not correlated with hepatitis severity in hepatitis C virus/HIV-coinfected individuals: implications for the therapeutic use of CCR5 antagonists
    Thierry Vincent
    , CNRS UPR 1142, Montpellier, France
    J Acquir Immune Defic Syndr 38:305-9. 2005
    ..In conclusion, we failed to demonstrate any impact of interindividual variability in T-cell surface CCR5 density on HCV infection, which would have argued against the use of CCR5 antagonists in HIV/HCV-coinfected subjects...
  43. ncbi Enumeration of latently infected CD4+ T cells from HIV-1-infected patients using an HIV-1 antigen ELISPOT assay
    Jean-Michel Fondere
    Departement de Virologie Clinique, , 371 Avenue du Doyen Giraud, 34295 Montpellier edex 5, France
    J Clin Virol 29:33-8. 2004
    ..CONCLUSION: As each immunospot represents one HIV-1 antigen-secreting cell, the HIV-1 ELISPOT assay is a powerful to enumerate circulating CD4(+) T lymphocytes latently infected with HIV-1...
  44. ncbi CXCR4 overexpression during the course of HIV-1 infection correlates with the emergence of X4 strains
    Yea Lih Lin
    Institut de Genetique Humaine, Montpellier, France
    J Acquir Immune Defic Syndr 39:530-6. 2005
    ..027). These data suggest that CXCR4 overexpression during the course of the disease in some patients could favor the emergence of X4 strains...
  45. ncbi Detection of peripheral HIV-1-specific memory B cells in patients untreated or receiving highly active antiretroviral therapy
    Jean-Michel Fondere
    Virology Laboratory, Hospital Lapeyronie, INSERM U470, , Hospital A. Villeneuve, France
    AIDS 17:2323-30. 2003
    ....
  46. ncbi Enfuvirtide (T-20) cross-reactive glycoprotein 41 antibody does not impair the efficacy or safety of enfuvirtide
    Sharon Walmsley
    University of Toronto, Toronto, Ontario, Canada
    J Infect Dis 188:1827-33. 2003
    ..Safety was unaffected by the presence of positive antibody at any time point or change in level of antibody. There was no evidence that enfuvirtide cross-reactive gp41 antibody affects the efficacy or safety of enfuvirtide...
  47. ncbi Intermittent viremia during first-line, protease inhibitors-containing therapy: significance and relationship with drug resistance
    Bernard Masquelier
    Département de Virologie et Immunologie, Hopital Pellegrin, Bordeaux, France
    J Clin Virol 33:75-8. 2005
    ..In HIV-infected patients on first-line antiretroviral therapy, the significance of intermittent viremia and their relationship with drug resistance remain unclear...
  48. ncbi Introduction of SARS in France, March-April, 2003
    Jean Claude Desenclos
    Département Maladies Infectieuses, Institut de Veille Sanitaire, Saint Maurice, France
    Emerg Infect Dis 10:195-200. 2004
    ..Timely detection, isolation of probable case-patients, and quarantine of their contacts appear to have been effective in preventing the secondary spread of SARS in France...
  49. ncbi Detection and enumeration of circulating HIV-1-specific memory B cells in HIV-1-infected patients
    Jean-Michel Fondere
    Laboratoire de Virologie, , Montpellier, France
    J Acquir Immune Defic Syndr 35:114-9. 2004
    ..We found that in AIDS patients, HIV-1-specific resting memory B cells circulate in the blood and can be quantified by their anti-HIV-1 antibody secretion after strong B cell polyclonal stimulation...
  50. ncbi Spontaneous secretion of immunoglobulins and anti-HIV-1 antibodies by in vivo activated B lymphocytes from HIV-1-infected subjects: monocyte and natural killer cell requirement for in vitro terminal differentiation into plasma cells
    Anne Marie Fournier
    , Centre Hospitalier et Universitaire, Montpellier, France
    Clin Immunol 103:98-109. 2002
    ....
  51. ncbi The chemokine CCL5 regulates the in vivo cell surface expression of its receptor, CCR5
    Yea Lih Lin
    Institut de Genetique Humaine, CNRS UPR1142, France
    AIDS 22:430-2. 2008
    ..Among the chemokines that bind to CCR5, and induce its internalization, CCL5 is the most abundant in vivo. We show that the level of CCL5 production is a main factor determining CD4+ T cell surface CCR5 density...
  52. ncbi Two case reports of symptomatic visceral leishmaniasis in AIDS patients concomitant with immune reconstitution due to antiretroviral therapy
    Antoine Berry
    Service des Maladies Infectieuses et Tropicales, Hopital Gui de Chauliac, Centre Hospitalier Universitaire, 34295 Montpellier Cedex 5, France
    Scand J Infect Dis 36:225-7. 2004
    ..The report raises the question whether a rapid immune reconstitution may convert a latent visceral leishmaniasis into a symptomatic one...
  53. ncbi Small dense LDL and atherogenic lipid profile in HIV-positive adults: influence of lopinavir/ritonavir-containing regimen
    Stephanie Badiou
    Department of Biochemistry, University Hospital, Montpellier 34295, France
    AIDS 17:772-4. 2003
  54. ncbi Nocardia veterana isolated from ascitic fluid of a patient with human immunodeficiency virus infection
    Sylvain Godreuil
    , , F-34295 Montpellier Cedex 5, France
    J Clin Microbiol 41:2768-73. 2003
    ..A phylogenetic analysis was conducted and showed that N. veterana was most closely related to the recently characterized species Nocardia africana rather than to Nocardia vaccinii, as previously reported...
  55. ncbi Association of apolipoproteins C3 and E with metabolic changes in HIV-infected adults treated with a protease-inhibitor-containing antiretroviral therapy
    Jean Marie Bard
    Faculte de Pharmacie, Laboratoire de Biochimie, Nantes, France
    Antivir Ther 11:361-70. 2006
    ....
  56. ncbi Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population
    Marianne Saves
    INSERM U593 ex U330, Universite Victor Segalen Bordeaux 2, Bordeaux, France
    Clin Infect Dis 37:292-8. 2003
    ....
  57. ncbi Fulminant varicella hepatitis in a human immunodeficiency virus infected patient: case report and review of the literature
    Catherine Lechiche
    Infectious and Tropical Diseases Unit, Centre Hospitalier Gui de Chauliac, Montpellier, France
    Scand J Infect Dis 38:929-31. 2006
    ..Varicella zoster virus is an uncommon cause of acute liver disease which occurs mainly in immunocompromised patients. Acyclovir is the cornerstone of the treatment...
  58. ncbi Fat microinfiltration autografting for facial restructuring in HIV patients
    Sophie Domergue
    Department of Maxillo-Facial and Oral Surgery, Head: Prof. Dr. P. Goudot, University Hospital of Montpellier, France
    J Craniomaxillofac Surg 34:484-8. 2006
    ..CONCLUSION: The results of this procedure after a maximum of 3 years postoperatively have been positive. However, there is a need of long-term experience with this method...
  59. ncbi Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection
    Daniel J Skiest
    University of Texas Southwestern Medical Center, Dallas, Texas
    Clin Infect Dis 44:607-14. 2007
    ....
  60. ncbi Suv39H1 and HP1gamma are responsible for chromatin-mediated HIV-1 transcriptional silencing and post-integration latency
    Isaure du Chéné
    Laboratoire de Virologie Moleculaire, Institut de Genetique Humaine, UPR 1142, Montpellier, France
    EMBO J 26:424-35. 2007
    ..Finally, we show in different cellular models, including PBMCs from HIV-1-infected donors, that HIV-1 reactivation could be achieved after HP1gamma RNA interference...
  61. ncbi Suppression of microRNA-silencing pathway by HIV-1 during virus replication
    Robinson Triboulet
    Laboratoire de Virologie Moleculaire, Institut de Genetique Humaine, Montpellier, France
    Science 315:1579-82. 2007
    ..Our results highlight the involvement of the miRNA-silencing pathway in HIV-1 replication and latency...
  62. ncbi Fenofibrate improves the atherogenic lipid profile and enhances LDL resistance to oxidation in HIV-positive adults
    Stephanie Badiou
    Laboratoire de Biochimie des Lipides, Department of Biochemistry, 371 Av du Doyen Gaston Giraud, , CHU Montpellier F34295, France
    Atherosclerosis 172:273-9. 2004
    ..CONCLUSION: Fenofibrate therapy improves the atherogenic lipid profile in HIV-positive adults with hypertriglyceridemia...
  63. ncbi Is tenofovir involved in hypophosphatemia and decrease of tubular phosphate reabsorption in HIV-positive adults?
    Stephanie Badiou
    Department of Biochemistry, University Hospital, F34295 Montpellier, France
    J Infect 52:335-8. 2006
    ..The aim of our study was to explore the effect of tenofovir on phosphatemia and on tubular phosphate reabsorption...